WHAT IS CLAIMED IS:

1. A pharmaceutical composition multi-unit dosage form comprising at least two discrete unit dosage forms bound to one another by a coating and/or matrix, each of said unit dosage forms comprising a therapeutically active agent and an absorption enhancer, said unit dosage forms together comprising a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said coating and/or matrix is formulated for immediate release of said unit dosage forms upon oral administration, the multi-unit dosage form being capable of disintegrating in gastric fluid and/or in saliva to thereby release said unit dosage forms, wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, wherein at least 50 weight percents of the unit dosage forms consists of said absorption enhancer, and wherein an area under curve (AUC) of plasma concentration of said therapeutically active agent upon oral administration of the multi-unit dosage form is characterized by an inter-subject coefficient of variation of less than 100 %.

2. The multi-unit dosage form of claim 1, wherein said coating and/or matrix is soluble in gastric fluid and/or in saliva.

3. The multi-unit dosage form of any one of claims 1 to 2, wherein said coating and/or matrix comprises a disintegrant.

4. The multi-unit dosage form of any one of claims 1 to 3, comprising from 3 to 10 of said discrete unit dosage forms.

5. The multi-unit dosage form of any one of claims 1 to 4, wherein said therapeutically active agent has a molecular weight in a range of 0.5 kDa to 100 kDa.

6. The multi-unit dosage form of any one of claims 1 to 4, wherein said therapeutically active agent is a BCS Class III agent.

7. The multi-unit dosage form of any one of claims 1 to 4, wherein said therapeutically active agent is a polypeptide.

8. The multi-unit dosage form of claim 7, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof.

9. Use of the multi-unit dosage form of any one of claims 1 to 8, in the manufacture of a medicament for the treatment of a condition treatable by oral administration of said therapeutically active agent in a subject in need thereof.

10. Use of a pharmaceutical composition unit dosage form comprising a therapeutically active agent and an absorption enhancer in the manufacture of a medicament for the treatment of a condition treatable by said therapeutically active agent, said treatment comprising concomitant oral administration of at least three of the unit dosage form, wherein said at least three of said unit dosage form are not comprised by a multi-unit dosage form and together comprise a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said therapeutically active agent is a BCS Class III agent and/or a polypeptide, and said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, wherein said treatment comprises reducing a variability of Cmax and/or AUC of plasma concentrations of said therapeutically active agent, as compared with a corresponding treatment by oral administration of a single unit dosage form having the same total composition as said at

least three unit dosage forms, and wherein at least 50 weight percents of the unit dosage form consists of said absorption enhancer.

11. The use of claim 10, wherein said treatment comprises concomitant oral administration of from 3 to 10 of the unit dosage form.

12. The use according to any one of claims 10 to 11, wherein said treatment comprises increasing a Cmax and/or a bioavailability of said therapeutically active agent, as compared with a corresponding treatment by oral administration of a single unit dosage form having the same total composition as said at least three unit dosage forms.

13. The use according to any one of claims 10 to 12, wherein said therapeutically active agent has a molecular weight in a range of 0.5 kDa to 100 kDa.

14. The use according to any one of claims 10 to 12, wherein said therapeutically active agent is said BCS Class III agent.

15. The use according to any one of claims 10 to 12, wherein said therapeutically active agent is said polypeptide.

16. The use according to claim 15, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof.

17. A pharmaceutical composition unit dosage form comprising less than 200 µg of parathyroid hormone or a fragment thereof, and an absorption enhancer selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, wherein the unit dosage form is not comprised by a multi-unit dosage form.

18. Use of the unit dosage form of claim 17, in the manufacture of a medicament for the treatment of a condition treatable by said parathyroid hormone or a fragment thereof, said treatment comprising concomitant oral administration of at least two of said unit dosage form, wherein said at least two of said unit dosage form together comprise a therapeutically effective amount of said parathyroid hormone or a fragment thereof and an effective amount of said absorption enhancer.

19. The use according to any one of claims 16 and 18, wherein said condition treatable by said parathyroid hormone or a fragment thereof is selected from the group consisting of hypoparathyroidism, osteoporosis, and a medical condition associated with a bone fracture and/or bone defect.

20. A kit comprising a plurality of sets of at least three unit dosage forms, said unit dosage forms comprising a therapeutically active agent and an absorption enhancer, wherein said at least three unit dosage forms are not comprised by a multi-unit dosage form and together comprise a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, and wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof.